Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06621602
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-23
Brief Title:
Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinsons Disease
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinsons Disease
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Syn-Q
Brief Summary:
This study aims to assess the levels of phosphorylated alpha-synuclein P-SYN in patients with Parkinsons disease and REM Behavior Disorder using a minimally invasive skin punch biopsy It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN quantification as a biomarker for disease progression
Detailed Description:
This is a prospective longitudinal study involving 75 Parkinsons disease patients and 25 patients with REM Behavior Disorder Each participant will undergo a baseline evaluation followed by follow-ups every six months over an 18-month period The evaluations will include clinical assessments neurologic exams and skin biopsies from three locations Data will be collected on disease progression and the amount of P-SYN in cutaneous nerve fibers
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None